(Q43759278)

English

A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients (English)

1 reference

Europe PubMed Central

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D Smith

1

1 reference

Europe PubMed Central

26 November 2017

G Hales

2

1 reference

Europe PubMed Central

26 November 2017

N Roth

3

1 reference

Europe PubMed Central

26 November 2017

M Law

4

1 reference

Europe PubMed Central

26 November 2017

J Ray

5

1 reference

Europe PubMed Central

26 November 2017

J Druett

6

1 reference

Europe PubMed Central

26 November 2017

J Mitchell

7

1 reference

Europe PubMed Central

26 November 2017

G Mills

8

1 reference

Europe PubMed Central

26 November 2017

N Doong

9

1 reference

Europe PubMed Central

26 November 2017

R Franklin

10

1 reference

Europe PubMed Central

26 November 2017

CHRN 025 Study Group. Community HIV Research Network

11

1 reference

Europe PubMed Central

26 November 2017

publication date

1 March 2001

1 reference

Europe PubMed Central

26 November 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

26 November 2017

2

1 reference

Europe PubMed Central

26 November 2017

97-107

1 reference

Europe PubMed Central

26 November 2017

2

1 reference

Europe PubMed Central

26 November 2017

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates.

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FCFYJ-26JF-VVRU-7AN8

21 January 2018

Identifiers

10.1310/CFYJ-26JF-VVRU-7AN8

1 reference

https://api.fatcat.wiki/v0/release/v3tuidb57fd63n2ig4uf332mda

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_v3tuidb57fd63n2ig4uf332mda

1 reference

https://api.fatcat.wiki/v0/release/v3tuidb57fd63n2ig4uf332mda

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/v3tuidb57fd63n2ig4uf332mda

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43759278&oldid=2103094131"